LIDE Banner 1

Preclinical Focus, Clinical Mindset

The path to successful drug development starts well before the clinic, in preclinical models that mirror real-world biology.
Review Our Technologies
previous arrow
next arrow

Best in class preclinical models for your research:

2300+ PDX Models
120 CDX Models
Orthotopic Models
Syngeneic Models
Humanized Models
Ex Vivo Models
Patient Samples
In-House Multi-Omics
MiniPDX
3D Organoids
2300+ PDX Models
120 CDX Models
Orthotopic Models
Syngeneic Models
Humanized Models
Ex Vivo Models
Patient Samples
In-House Multi-Omics
MiniPDX
3D Organoids

2300 PDX Models available across 50+ Cancer Types

  • 400+ pre-treated
  • 370+ drug resistant
  • 350+ treatment naive
  • ~300 models warmed and ready
Contact Us
  • Patient consent & treatment history
  • Gene mutation & expression data
  • Growth curves and SOC
  • Search by indication, genotype or phenotype
Request Access

Our Story

LIDE Biotech is an oncology-focused, preclinical CRO with China-based, AAALAC accredited labs. Founded in 2011 by overseas returnees, LIDE's founding vision is rooted in a translational mindset, leveraging tools that bring preclinical studies as close as possible to clinical relevance.

Whether you're in San Francisco, Stockholm, or Shanghai, our promise is the same: a robust preclinical platform delivering clinically relevant results.

Learn more about us ›

Built on Trust

Partnering with LIDE is designed to be straightforward, flexible, and responsive. From first discussions to study delivery, our Scientific Engagement and Business Development teams guide you through each step to ensure smooth collaboration.

Partnering with a new CRO can be difficult and time consuming. At LIDE, engagement can be summarized into 5 major steps:

1. Confidentiality
2. Study Consultation
3. Model Selection
4. Shipping Compounds
5. Timeline Review
1. Confidentiality
2. Study Consultation
3. Model Selection
4. Shipping Compounds
5. Timeline Review
Learn more ›